Holding Recce during the current market climate has been very painful but it just hasn't been the right macro environment for speculative clinical and preclinical companies.
I look forward to seeing if the suggested timelines are met for the DFU and UTI study. No one can deny things have fallen behind (with all the trials) but its hard to tell why or what is going on in the background, it may just be COVID
Obviously cash will need to be raised in the next 12-24 months so it will be interesting what catalysts will support the share price before a capital raise for sophisticated and professional investors just like last time. Retail investors missed out then and will probably miss out again which is very unfair. The silver lining was the share price crashed, along with help from a shorter or two so retail could get much better prices in the months following
RCE Price at posting:
70.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)